Cargando…

Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

Detalles Bibliográficos
Autores principales:	Llibre, Josep M., Cahn, Pedro E., Barber, Tristan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102621/ https://www.ncbi.nlm.nih.gov/pubmed/35572577 http://dx.doi.org/10.3389/fimmu.2022.904689

Ejemplares similares

Response to Commentary: Long-term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens
por: Serrano-Villar, Sergio, et al.
Publicado: (2022)

Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens
por: Serrano-Villar, Sergio, et al.
Publicado: (2022)

Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
por: Llibre, Josep M, et al.
Publicado: (2022)

Hidden costs of antiretroviral treatment: the public health efficiency of drug packaging
por: Andreu-Crespo, Àngels, et al.
Publicado: (2015)

Hidden costs of HIV treatment in Spain: inefficiency of the antiretroviral drug packaging
por: Llibre-Codina, Josep M, et al.
Publicado: (2014)

Humanized Mouse Model Mimicking Pathology of Human Tuberculosis for in vivo Evaluation of Drug Regimens
por: Arrey, Frida, et al.
Publicado: (2019)

Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain
por: Llibre, Josep M, et al.
Publicado: (2013)

Antiretroviral Treatment Simplification With 2-Drug Regimens: Impact of Transmitted Drug Resistance Mutations
por: Kessler, Harald H, et al.
Publicado: (2019)

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
por: Balkundi, Shantanu, et al.
Publicado: (2010)

The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs
por: Van Dyke, Russell B., et al.
Publicado: (2016)

Preferred antiretroviral drugs for the next decade of scale up
por: Andrieux-Meyer, Isabelle, et al.
Publicado: (2012)

How Monocytes Contribute to Increased Risk of Atherosclerosis in Virologically-Suppressed HIV-Positive Individuals Receiving Combination Antiretroviral Therapy
por: Jaworowski, Anthony, et al.
Publicado: (2019)

Persistence of Activated and Adaptive-Like NK Cells in HIV(+) Individuals despite 2 Years of Suppressive Combination Antiretroviral Therapy
por: Hearps, Anna C., et al.
Publicado: (2017)

Potential drug–drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals
por: Mukonzo, Jackson, et al.
Publicado: (2019)

Do Antiretroviral Drugs Protect From Multiple Sclerosis by Inhibiting Expression of MS-Associated Retrovirus?
por: Morandi, Elena, et al.
Publicado: (2019)

Evaluation of the adverse reactions of antiretroviral drug regimens in a tertiary care hospital
por: Rather, Zahoor A., et al.
Publicado: (2013)

Treatment outcome of different antiretroviral drug regimens in HIV-positive pregnant women
por: Chauhan, Nidhi, et al.
Publicado: (2021)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

978. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV
por: Mounzer, Karam, et al.
Publicado: (2019)

Potential drug-drug interactions of antiretrovirals and antimicrobials detected by three databases
por: Vivithanaporn, Pornpun, et al.
Publicado: (2021)

Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV
por: Martínez-Sanz, Javier, et al.
Publicado: (2022)

Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study
por: Masiá, Mar, et al.
Publicado: (2016)

Commentary: Mutual interaction of basophils and T cells in chronic inflammatory diseases
por: Chirumbolo, Salvatore
Publicado: (2016)

Viral dissemination and immune activation modulate antiretroviral drug levels in lymph nodes of SIV-infected rhesus macaques
por: Srinivasula, Sharat, et al.
Publicado: (2023)

Differential Frequencies of Intermediate Monocyte Subsets Among Individuals Infected With Drug-Sensitive or Drug-Resistant Mycobacterium tuberculosis
por: Sampath, Pavithra, et al.
Publicado: (2022)

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
por: Llibre, Josep M, et al.
Publicado: (2022)

1284. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens
por: Pierone, Gerald, et al.
Publicado: (2022)

Differential Responsiveness of the Platelet Biomarkers, Systemic CD40 Ligand, CD62P, and Platelet-Derived Growth Factor-BB, to Virally-Suppressive Antiretroviral Therapy
por: Steel, Helen C., et al.
Publicado: (2021)

Molecular dissection of Janus kinases as drug targets for inflammatory diseases
por: Kwon, Sunghark
Publicado: (2022)

Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection
por: Mondi, Annalisa, et al.
Publicado: (2022)

Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?
por: Bukkems, Vera E., et al.
Publicado: (2020)

Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma
por: Gao, Xiaozhuo, et al.
Publicado: (2022)

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
por: Boffito, Marta, et al.
Publicado: (2020)

Commentary
por: Carbone, June, et al.
Publicado: (2014)

Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations
por: Castells, Mariana
Publicado: (2017)

Commentary: Mechanisms of kwashiorkor-associated immune suppression: Insights from human, mouse, and pig studies
por: Gonzales, Gerard Bryan, et al.
Publicado: (2022)

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2018)

Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study
por: Abbas, Ume L., et al.
Publicado: (2019)

Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens
por: Pinto-Cardoso, Sandra, et al.
Publicado: (2017)

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway
por: Anliker-Ort, Marion, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bnerad7l3orm1vtl2r4k7n7m31